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ABSTRACT 
Objective: The present investigation concerns the design and evaluation of floating tablets of Levofloxacin, which after oral administration prolong 
the gastric residence time and increased drug bioavailability.  
Methods: Levofloxacin is a synthetic chemotherapeutic agent used to treat severe or life-threatening bacterial infections. The present work was 
designed to formulate floating tablet of Levofloxacin with various swelling agents. Formulations were prepared using various concentrations of 
Guar gum, Carbopol, hydroxy propyl methyl cellulose and Ethyl Cellulose by direct compression technique. The selected batches were evaluated for 
various parameters like weight variation, thickness, diameter, friability, floating lag time, duration of floating, swelling index, content uniformity and 
in-vitro drug release. The data obtained from the in-vitro dissolution studies of optimized batch F7 were fitted in different models.  
Results: The optimized formulation F7 showed 99.25% drug content, floating lag time of 10 min and swelling index of 40%. Drug release 
mechanism was found to be zero order along with higuchi release kinetics exhibiting diffusion along with dissolution of the drug from the tablet by 
non fickian mechanism. 
Conclusion: Levofloxacin floating tablets exhibited increased gastric residence time, there by improved bioavailability and therapeutic effect of the drug. 
Keywords: Levofloxacin, Gastro retentive, Guar gum, Hydroxy propyl methyl cellulose, Ethyl Cellulose, Carbopol.  
 
INTRODUCTION 
Oral controlled drug delivery system provides the continuous oral 
delivery of drugs at predictable and reproducible kinetics for a 
predetermined period throughout the course of Gastro Intestinal 
(GI) transit. Conventional oral controlled dosage forms suffer from 
mainly two adversities the short gastric retention time and 
unpredictable gastric emptying time [1]. A relatively short GI transit 
time of most drug products impedes the formulation of single daily 
dosage forms. Altering the gastric emptying can overwhelm these 
problems. Therefore it is desirable, to formulate a controlled release 
dosage form that gives an extended GI residence time. One of the 
most feasible approaches for achieving a prolonged and predictable 
drug delivery profiles in the gastrointestinal tract is to control the 
gastric residence time using gastro retentive dosage forms that offer 
a new and better option for drug delivery [2]. 
Dosage forms that can be retained in the stomach are called gastro 
retentive drug delivery systems. Gastro retentive systems can 
remain in the gastric region for several hours and hence significantly 
prolong the gastric residence time of drugs. Prolonged gastric 
retention improves bioavailability, reduces drug waste, and improves 
solubility for drugs that are less soluble in a high pH environment [3]. 
Gastro retentive floating tablets have been emerged as an efficient 
means of enhancing the bioavailability of many drugs. Rapid gastro-
intestinal transit could result in incomplete drug release from the drug 
delivery system above the absorption zone leading to diminished 
efficacy of administered dose [4]. 
Levofloxacin is a synthetic chemotherapeutic antibiotic of the 
fluoroquinolone drug class and is used to treat severe or life-
threatening bacterial infections or bacterial infections that have 
failed to respond to other antibiotic classes [5]. Levofloxacin is a 
broad-spectrum antibiotic, inhibiting DNA gyrase, a type II 
topoisomerase, and topoisomerase IV, which is an enzyme necessary 
to separate replicated DNA, thereby inhibiting cell division [6]. 
The bioavailability of Levofloxacin hemihydrate is above 99% with a 
plasma half-life of 6–8 h. It is freely soluble in pH 0.6 to 5.8 ranges. Above 
pH 5.8, the solubility increases rapidly to its maximum at pH 6.7 and 
above which the solubility decreases and reaches a minimum value at a 
pH of approximately 6.9. Thus solubility of the drug is reduced in 
intestinal alkaline pH. [7] Hence, it was selected in the present 
investigation as a suitable candidate for the design of gastric floating 
drug delivery system for improved retention time and bioavailability. 
The present study is to develop a floatable drug delivery system of 
Levofloxacin using hydroxy propyl methyl cellulose, Guar gum, 
Carbopol, Ethyl cellulose for sustained drug delivery and gastric 
retentive property. Thus the study aims to improve the oral 
bioavailability of the drug and to achieve extended retention in the 
stomach which may result in prolonged absorption 
MATERIALS AND METHODS 
Materials  
Levofloxacin was received as a gift sample from Srini Pharmaceuticals, 
Nalgonda. Guar gum was obtained as a gift sample from Colorcon Asia 
Pvt. Ltd, Goa, India. Hydroxy Propyl Methylcellulose, Micro Crystalline 
Cellulose, Magnesium stearate, Sodium bicarbonate, Talc, Carbopol, 
Ethyl cellulose, Poly vinyl pyrolidone K 30 were procured from S. D. 
Fine Chem. Ltd, Mumbai, India. 
Preparation of floating tablets of levofloxacin  
Levofloxacin floating tablets were prepared by direct compression 
method employing sodium bicarbonate as gas-generating agent. Guar 
gum, Carbopol and Ethyl cellulose were used as rate controlling 
polymers. The concentrations of the excipients were optimized as 
showed in table 1. The drug was mixed with the rate retarding polymers 
and other excipients in ascending order of their weights. The powder 
mix was blended for 20 min to have uniform distribution of drug in the 
formulation. Then magnesium Stearate and Talc were added. About 650 
mg of the powder mix was weighed accurately and fed into the die and 
compressed using 12 mm round surface punches [8]. 
Evaluation of levofloxacin floating tablets 
Levofloxacin floating tablets were subjected to post compression 
parameters like weight variation, hardness, friability, floating time, 
total floating time, in-vitro dissolution, swelling index, in-vitro 
buoyancy, drug content and stability studies. 
Weight variation 
The formulated tablets were tested for weight uniformity. 20 tablets 
were weighed collectively and individually. From the collective 
weight, average weight was calculated. Each tablet weight was then 
compared with the average weight to ascertain whether it is within 
permissible limits or not [9]. 
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Table 1: Composition of levofloxacin floating tablets 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Levofloxacin 250 250 250 250 250 250 250 250 250 250 250 250 
Hydroxy propyl methyl cellulose 20 - - - - - - - - - - - 
Guar gum - 20 - 20 10 - 30 35 30 35 40 40 
Carbopol - - 20 10 - 20 - 5 - - - - 
Ethyl cellulose - - - - 5 5 5 5 10 10 5 10 
Sodium bicarbonate 15 15 15 15 15 15 15 15 15 15 15 15 
Poly vinyl pyrolidone K 30 5 5 5 5 5 5 5 5 5 5 5 5 
Microcrystalline cellulose 55 55 55 45 60 50 40 30 35 30 30 25 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Magnesium stearate 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Total weight  650 650 650 650 650 650 650 650 650 650 650 650 
 
Hardness  
The tablet crushing strength, which is the force required to break the 
tablet by compression in the diametric direction was measured in 
triplicate using Pfizer tablet hardness tester. 
Friability 
The Roche friability test apparatus was used to determine the 
friability of the tablets. 20 pre weighed tablets were placed in the 
apparatus, which was subjected to 100 revolutions. Then the tablets 
were reweighed. The percentage friability was calculated using the 
formula [10]. 
 
Determination of swelling index 
The swelling index of tablets was determined in 0.1N Hcl (pH 1.2) at 
room temperature. The swollen weight of the tablet was determined 
at predefined time intervals over a period of 24 h. The swelling index 
(SI), expressed as a percentage, and was calculated from the 
following equation [11]. 
 
In vitro buoyancy studies 
In-vitro buoyancy studies were performed for all the twelve 
formulations as per the method described by Rosa et al. The 
randomly selected tablets from each formulation were kept in a 100 
ml beakers containing simulated gastric fluid, pH 1.2 as per USP. The 
time taken for the tablet to rise to the surface and float was taken as 
floating lag time (FLT). The duration of time the dosage form 
constantly remained on the surface of the medium was determined 
as the total floating time (TFT) [12]. 
Drug content estimation 
The drug content in each formulation was determined by triturating 
20 tablets and powder equivalent to an average weight was added in 
100 ml of 0.1N HCL, followed by stirring for 30 minutes. The solution 
was filtered through a 0.45μ membrane filter, diluted suitably and 
the absorbance of resultant the solution was measured 
spectrophotometrically at 288 nm using 0.1 N HCL as blank.  
In-vitro dissolution studies  
In-vitro drug release of the samples was carried out using USP–type 
II dissolution apparatus at 37±0.5ºc using 900 ml of 0.1N Hcl as the 
dissolution medium at 50 rpm speeds. One Levofloxacin tablet was 
placed in each basket and was allowed to run for 12 hours. Aliquot of 
5 ml was withdrawn at predetermined time interval and equivalent 
amount of fresh medium was replaced to maintain a constant 
volume. Collected samples were suitably diluted with 0.1N Hcl and 
analyzed at 288 nm using 0.1N Hcl as blank. The drug content was 
calculated using the equation generated from the standard curve. 
The %cumulative drug release was calculated [13]. 
Study of release kinetics 
The dissolution data were fitted into various kinetic models to 
determine the release mechanisms. Different kinetic equations (zero 
order, First order, and Higuchi’s equations) were applied to 
interpret the release rate of the drug from the matrix system. For 
prediction of the mechanism of drug release through polymeric 
system Korsmeyer and Peppas, developed a mathematical equation, 
relating exponentially the drug released to the elapsed time. It is a 
simple semi empirical equation also called as Power law.  
Mt/M∞ = Kt n 
Where, Mt/M∞ is the fraction of drug released at time ͑ t’ and infinite 
time, ͑ k’ is the kinetic constant, n is the drug release exponent, 
indicative of the mechanism of drug release. 
 
Exponent, n Drug Release Mechanism 
Thin Film Cylinder Sphere 
0.5 0.45 0.43 Fickian Diffusion 
0.5<n<1.0 0.45<n<0.89 0.43<n<0.85 Anomalous Transport 
1.0 0.89 0.85 Case II transport 
 
Mean dissolution time (MDT) is used to characterize the drug 
release rate from the dosage form and retarding efficiency of the 
polymer. MDT was calculated using the equation:  
MDT = n/(n+1) * k-1/n 
Where ͑ n’ is the release component and ͑ k’ is the kinetic constant 
calculated from the power law [14]. 
RESULTS AND DISCUSSION 
Levofloxacin floating tablets were developed to increase the gastric 
residence time of the drug, so that they can be retained in the 
stomach for longer time and help in controlled release of the drug to 
a minimum of 12h. The tablets were made using different gel 
forming polymers such as Guar gum, carbopol and ethyl cellulose by 
direct compression method. When a combination of gas entrapping 
as well as controlled release system is there, the use of 
disintegrating agent is important which does not quickly break the 
matrix and allows slow disintegration of the swollen matrix. Poly 
vinyl pyrolidone K 30 in an optimized concentration was employed 
for such unique disintegration properties. Talc and magnesium 
stearate were employed for their glidant and lubricant property. The 
prepared formulations were evaluated for physical characters like 
tablet hardness, friability, weight variation buoyancy lag time, total 
floating time, in-vitro drug release and drug release kinetics. 
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Table 2: Post compression evaluation of levofloxacin floating tablets 
Formulation code Weight variation a (mg)  Thickness b (mm) Hardnessa (kg/cm2)  Friabilitya(%) 
F1 651±2.33 4.15±0.10 6.3±0.05 0.33±0.10 
F2 650±2.94 4.13±0.05 6.5±0.10 0.30±0.04 
F3 649±3.77 4.16±0.05 6.3±0.12 0.33±0.07 
F4 650±1.50 4.14±0.10 6.5±0.05 0.34±0.17 
F5 649±3.30 4.17±0.05 6.2±0.10 0.36±0.08 
F6 647±2.83 4.12±0.10 6.6±0.05 0.41±10.12 
F7 648±2.33 4.18±0.06 6.2±0.09 0.42±0.05 
F8 650±3.11 4.14±0.05 6.4±0.04 0.35±0.12 
F9 652±2.56 4.16±0.09 6.3±0.10 0.37±0.04 
F10 650±2.14 4.14±0.05 6.5±0.05 0.40±0.08 
F11 651±1.85 4.18±0.05 6.2±0.04 0.38±0.12 
F12 649±2.35 4.13±0.05 6.4±0.10 0.42±0.07 
aData shown are as an average n = 20, bData shown are as an average n = 10 
 
Table 3: Evaluation of drug content, floating lag time, swelling index and total floating time for the prepared formulations 
Formulation code Drug content (%) n = 20 Floating lag time (Min) Swelling index (%) Floating duration (H) 
F1 99.49±0.91 5 min 25 sec -- Fail 
F2 99.55±0.92 4 min 33 sec 38.09 8 
F3 99.41±0.34 3 min 32 sec -- Fail 
F4 99.72±1.39 3 min 22 sec -- Fail 
F5 99.84±1.69 15 min 12 sec -- Fail 
F6 99.30±1.07 15 min 34 sec -- Fail 
F7 99.25±1.81 10 min 12 sec 40.90 12 
F8 99.54±0.37 10 min 24 sec 40.20 12 
F9 98.50±0.91 2 min 21 sec -- Fail 
F10 99.26±1.65 5 mins 36.83 12 
F11 98.30±0.85 3 mins 23 sec 22.05 12 
F12 99.45±0.98 12 mins 27.69 12 
 
Post compression parameters of Levofloxacin tablets 
Levofloxacin floating tablets were evaluated for post compression 
parameters like weight variation, thickness hardness, and friability. 
All the formulations remained off white, smooth, flat faced circular 
with no visible cracks. The results are shown in table 2. 
Weight variation 
The prepared tablets were evaluated for weight variation and were in 
the range of 647±2.83 to 651±2.33. The percent deviation from the 
average weight was found to be within the prescribed official limits.  
Thickness 
The thickness of the tablets was measured using vernier callipers. The 
thickness of the tablets ranged between 4.12±0.10 to 4.18±0.06 mm.  
Hardness 
Hardness of the tablets was measured by Monsanto tester. Tablet 
hardness reflects differences in tablet density and porosity, which 
are supposed to result in difference release patterns of the drug by 
affecting the rate of penetration of the dissolution fluid at the surface 
of the tablet. Hardness of the tablets was found to be between 6.2 to 
6.6 kg/m2. The tablets were found to be of good tensile strength.  
Friability 
Friability was measured by Roche Friabilator and found to be 0.30 to 
0.42, the friability of all the tablets was to be less than 1% which is 
an indication of satisfactory mechanical resistance of the tablets. 
Drug content 
The drug content was in the range of 98.30±0.85 to 99.84±1.69% 
which reflects good uniformity in drug content among different 
formulations.  
Floating lag time 
The time taken for the tablets to rise to the surface and float is the 
floating lag time. The gas generated is trapped and protected within 
the gel, formed by hydration of the polymer, thus decreasing the 
density of the tablet. As the density of the tablet falls below 1, the 
tablet became buoyant. The floating lag time ranged between 2 min 
21 sec to 15 min 34 sec.  
In-vitro dissolution studies for the prepared formulations 
The in-vitro dissolution was carried out for all the batches for 12 h. 
Formulations F1, F3, F4, F5, F6 and F9 showed no floating properties 
as they are containing high amount of carbopol which lead to 
formation of a viscous gel. Large concentration of high viscosity 
polymer induces the formation of strong viscous gel layer that 
slowed down the rate of water diffusion into the tablet matrix, which 
may result in retardation or decreases the drug release. The 
percentage release of drug varied for different batches. Formulation 
F7 containing 30% of Guar gum and 5% ethyl cellulose showed 
98.79% of drug release at the end of 12 h.  
 
 
Fig. 1: In-vitro release profile for F2, F7, F8, F10, F11 and F12 
formulations 
 
Release kinetics 
The data obtained from the in-vitro dissolution studies of optimized 
batch F7 were fitted in different models viz. Zero order, first order, 
Korsemeyer-Peppa’s model, Higuchi model and Hixson-Crowell 
model. Release kinetics results as shown in table 4. 
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Table 4: Release kinetics of F7 formulation 
Formulation code Zero order First order Higuchi model Peppas model 
F7 0.926 0.797 0.990 0.570 
 
It was found that, all the tablet formulations follow diffusion, 
dissolution mechanism for all drug release. F7 formulations followed 
diffusion along with dissolution of the drug from the tablet by non 
fickian mechanism. Drug release mechanism was found to be zero 
order along with higuchi release kinetics exhibiting diffusion along 
with dissolution of the drug from the tablet by non fickian mechanism. 
CONCLUSION 
Gastro-retentive controlled drug delivery system of Levofloxacin 
was prepared to increase the therapeutic effect of the drug by 
releasing the drug at the proximal part of the small intestine. 
Levofloxacin is used in eradication of Helicobacter Pylori and other 
bacterial infections. Levofloxacin floating tablets were prepared 
using of Guar gum, carbopol, hydroxy propyl methyl cellulose and 
Ethyl Cellulose in various ratios by direct compression technique 
employing sodium bicarbonate as gas-generating agent. According 
to the above results, formulation F7offered best controlled release 
along with floating lag time of 10 min 12 sec and total floating time 
of 12 h and in-vitro drug release of 98.79% at the end of 12 h.  
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